pre-IPO PHARMA

COMPANY OVERVIEW

Agilis Biotherapeutics is advancing innovative DNA therapeutics designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Rare Diseases

  • WEBSITE

    https://www.agilisbio.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Aug 23, 2018

    PTC Therapeutics Successfully Completes Acquisition of Agilis Biotherapeutics


    May 16, 2018

    Agilis Biotherapeutics Conducts a Scientific Symposium for Education and Awareness of AADC Deficiency at the 21st Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)


    May 14, 2018

    Agilis Biotherapeutics Announces Data Presentations on AADC Deficiency at the American Society of Gene and Cell Therapy 2018 Annual Meeting


    May 2, 2018

    Agilis Biotherapeutics Presents on Gene Therapy Pricing Strategies at the 2nd Annual Gene Therapy for Rare Disorders Summit


    Apr 24, 2018

    Agilis Biotherapeutics Presents Platform Paper on AADC Deficiency Gene Therapy at American Academy of Neurology Annual Meeting


    For More Press Releases


    Google Analytics Alternative